Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: Old and new insights on the effects of dopamine receptor pharmacology

Frontiers in Neurology

Volumn 5 APR, Issue , 2014, Pages

  Cerasa, Antonio ^a   Fasano, Alfonso ^b   Morgante, Francesca ^c   Koch, Giacomo ^d   Quattrone, Aldo ^a,e  

^a CNR   (Italy)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY OF MESSINA   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Dopaminergic treatment; Hyperkinetic movement disorders; Inferior frontal cortex; Levodopa induced dyskinesias; Tardive dyskinesias

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR; LEVODOPA;

ARTICLE; BRAIN CORTEX; BRAIN REGION; BRAIN SIZE; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DYSKINESIA; FRONTAL CORTEX; GRAY MATTER; HUMAN; MENTAL DISEASE; MOTOR CORTEX; NERVE CELL PLASTICITY; PARKINSON DISEASE; PATHOGENESIS; RECEPTOR BLOCKING; SUBTHALAMIC NUCLEUS; SYNAPSE; TARDIVE DYSKINESIA;

EID: 84901035168     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2014.00049     Document Type: Article

References (59)

1. Castrén E, Hen R. Neuronal plasticity and antidepressant actions. Trends Neurosci (2013) 36(5):259-67. doi: 10.1016/j.tins.2012.12.010.
2. Quartarone A, Siebner HR, Rothwell JC. Task-specific hand dystonia: can too much plasticity be bad for you? Trends Neurosci (2006) 29(4):192-9. doi:10.1016/j.tins.2006.02.007.
3. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci (1999) 22:105-22. doi:10.1146/annurev.neuro.22.1.105.
4. Byl NN, Merzenich MM, Jenkins WM. A primate genesis model of focal dystonia and repetitive strain injury: I. Learning-induced dedifferentiation of the representation of the hand in the primary somatosensory cortex in adult monkeys. Neurology (1996) 47:508-20. doi:10.1212/WNL.47.2.508.
5. Cenci MA. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci (2007) 30(5):236-43. doi:10.1016/j.tins.2007.03.005.
6. Breakefield XO, Blood AJ, Li Y, Hallett M, Hanson PI, Standaert DG. The pathophysiological basis of dystonias. Nat Rev Neurosci (2008) 9(3):222-34. doi:10.1038/nrn2337.
7. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord (2012) 27(10):1205-15. doi:10.1002/mds.25107.
8. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci (2000) 23(10):S8-19. doi:10.1016/S1471-1931(00)00028-8.
9. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci (2008) 9(9):665-77. doi:10.1038/nrn2471.
10. Rascol O, Sabatini U, Brefel C, Fabre N, Rai S, Senard JM, et al. Cortical motor overactivation in parkinsonian patients with levodopa-induced peak-dose dyskinesia. Brain (1998) 121(3):527-33. doi:10.1093/brain/121.3.527.
11. Brooks DJ, Piccini P, Turjanski N, Samuel M. Neuroimaging of dyskinesia. Ann Neurol (2000) 47(4):S154-8.
12. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 129(Pt 4):1059-69. doi:10.1093/brain/awl031.
13. Kishore A, Popa T, Velayudhan B, Joseph T, Balachandran A, Meunier S. Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced. Parkinson's disease. Brain (2012) 135(7):2074-88. doi:10.1093/brain/aws124.
14. Koch G, Brusa L, Caltagirone C, Peppe A, Oliveri M, Stanzione P, et al. rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease. Neurology (2005) 65:623-5. doi:10.1212/01.wnl.0000172861.36430.95.
15. Koch G. rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets. Restor Neurol Neurosci (2010) 28(4):561-8. doi:10.3233/RNN-2010-0556.
16. Koch G, Brusa L, Carrillo F, Lo Gerfo E, Torriero S, Oliveri M, et al. Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease. Neurology (2009) 73:113-9. doi:10.1212/WNL.0b013e3181ad5387.
17. Kishore A, Popa T, Balachandran A, Chandran S, Pradeep S, Backer F, et al. Cerebellar sensory processing alterations impact motor cortical plasticity in Parkinson's disease: clues from dyskinetic patients. Cereb Cortex (2013). doi:10.1093/cercor/bht058.
18. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol (1995) 18(3):197-214. doi:10.1097/00002826-199506000-00001.
19. Sigwald J, Bouttier D, Raymondeaud C, Piot C. [4 Cases of faciobucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics]. Rev Neurol (Paris) (1959) 100:751-5 [Article in French].
20. Baldessarini RJ, Tarsy D. Mechanisms underlying tardive dyskinesia. Res Publ Assoc Res Nerv Ment Dis (1976) 55:433-46.
21. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 10(1):55-72. doi:10.1017/S003329170003960X.
22. Calabresi P, De Murtas M, Mercuri NB, Bernardi G. Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission. Ann Neurol (1992) 31(4):366-73. doi:10.1002/ana.410310404.
23. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry (2000) 61(Suppl 4):5-9.
24. Ananth J. Current psychopathological theories of tardive dyskinesia and their implications for future research. Neuropsychobiology (1982) 8(4):210-22. doi:10.1159/000117901.
25. Peralta V, Campos MS, De Jalon EG, Cuesta MJ. Motor behavior abnormalities in drug-naïve patients with schizophrenia. Mov Disord (2010) 25(8):1068-76. doi:10.1002/mds.23050.
26. Crow TJ, Cross AJ, Johnstone EC, Owen F, Owens DG, Waddington JL. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol (1982) 2(5):336-40. doi:10.1097/00004714-198210000-00010.
27. Calabresi P, Giacomini P, Centonze D, Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol (2000) 47:S60-8.
28. Gottwald MD, AminoffMJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol (2011) 69(6):919-27. doi:10.1002/ana.22423.
29. Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, et al. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One (2010) 5(12):e15298. doi:10.1371/journal.pone.0015298.
30. Zesiewicz TA. Parkinson disease: the controversy of levodopa toxicity in Parkinson disease. Nat Rev Neurol (2011) 8(1):8-10. doi:10.1038/nrneurol.2011.199.
31. Spencer JP, Jenner A, Butler J, Aruoma OI, Dexter DT, Jenner P, et al. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic Res (1996) 24(2):95-105. doi:10.3109/10715769609088005.
32. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 351:2498-508. doi:10.1056/NEJMoa033447.
33. Cerasa A, Messina D, Pugliese P, Morelli M, Lanza P, Salsone M, et al. Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study. Mov Disord (2011) 26(5):807-12. doi:10.1002/mds.23660.
34. Aron AR, Robbin TW, Poldrack RA. Inhibition and the right inferior frontal cortex. Trends Cogn Sci (2004) 8(4):170-7. doi:10.1016/j.tics.2004.02.010.
35. Salgado-Pineda P, Delaveau P, Falcon C, Blin O. Brain T1 intensity changes after levodopa administration in healthy subjects: a voxel-based morphometry study. Br J Clin Pharmacol (2006) 62:546-51. doi:10.1111/j.1365-2125.2006.02695.x.
36. Cerasa A, Morelli M, Augimeri A, Salsone M, Novellino F, Gioia MC, et al. Prefrontal thickening in PD with levodopa-induced dyskinesias: new evidence from cortical thickness measurement. Parkinsonism Relat Disord (2013) 19(1):123-5. doi:10.1016/j.parkreldis.2012.06.003.
37. Cerasa A, Salsone M, Morelli M, Pugliese P, Arabia G, Gioia MC, et al. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias. Parkinsonism Relat Disord (2013) 19(10):883-8. doi:10.1016/j.parkreldis.2013.05.015.
38. Vernon AC, Modo M. Do levodopa treatments modify the morphology of the parkinsonian brain? Mov Disord (2012) 27(1):166-7. doi:10.1002/mds.24018.
39. Aron AR, Obeso J. Is executive control used to compensate for involuntary movements in levodopa-induced dyskinesia? Mov Disord (2012) 27(3):339-40. doi:10.1002/mds.24936.
40. Picconi B, Pisani A, Barone I, Bonsi P, Centonze D, Bernardi G, et al. Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology (2005) 26(5):779-83. doi:10.1016/j.neuro.2005.02.002.
41. Sgambato-Faure V, Cenci MA. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol (2012) 96(1):69-86. doi:10.1016/j.pneurobio.2011.10.005.
42. Cenci MA, Konradi C. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res (2010) 183:209-33. doi:10.1016/S0079-6123(10)83011-0.
43. Ahmed I, Bose SK, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G, et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain (2011) 134(Pt 4):979-86. doi:10.1093/brain/awr028.
44. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain (2007) 130(7):1819-33. doi:10.1093/brain/awm082.
45. de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol (2001) 49(3):298-303. doi:10.1002/ana.65.
46. de la Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain (2004) 127(4):888-99. doi:10.1093/brain/awh102.
47. Rylander D, Parent M, O'Sullivan SS, Dovero S, Lees AJ, Bezard E, et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol (2010) 68(5):619-28. doi:10.1002/ana.22097.
48. Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC. Cognitive inflexibility after prefrontal serotonin depletion. Science (2004) 304(5672):878-80. doi:10.1126/science.1094987.
49. Cerasa A, Cherubini A, Quattrone A, Gioia MC, Magariello A, Muglia M, et al. Morphological correlates of MAO A VNTR polymorphism: new evidence from cortical thickness measurement. Behav Brain Res (2010) 211(1):118-24. doi:10.1016/j.bbr.2010.03.021.
50. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry (2004) 65(Suppl 9):25-8.
51. Crow TJ, Ball J, Bloom SR, Brown R, Bruton CJ, Colter N, et al. Schizophrenia as an anomaly of development of cerebral asymmetry. A postmortem study and a proposal concerning the genetic basis of the disease. Arch Gen Psychiatry (1989) 46(12):1145-50. doi:10.1001/archpsyc.1989.01810120087013.
52. Pakkenberg B. Post-mortem study of chronic schizophrenic brains. Br J Psychiatry (1987) 151:744-752. doi:10.1192/bjp.151.6.744.
53. Heckers S. Neuropathology of schizophrenia: cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems. Schizophr Bull (1997) 23(3):403-21. doi:10.1093/schbul/23.3.403.
54. Jellinger K. The neuropathology of schizophrenia. J Neuropathol Exp Neurol (1999) 58(11):1192.
55. Vernon AC, Natesan S, Crum WR, Cooper JD, Modo M, Williams SC, et al. Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry (2012) 71(10):855-63. doi:10.1016/j.biopsych.2011.12.004.
56. Li CT, Chou KH, Su TP, Huang CC, Chen MH, Bai YM, et al. Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study. PLoS One (2013) 8(8):e71034. doi:10.1371/journal.pone.0071034.
57. Ganos C, Kühn S, Kahl U, Schunke O, Brandt V, Bäumer T, et al. Prefrontal cortex volume reductions and tic inhibition are unrelated in uncomplicated GTS adults. J Psychosom Res (2014) 76:84-7. doi:10.1016/j.jpsychores.2013.10.014.
58. Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res (2002) 43(2):111-7. doi:10.1016/S0168-0102(02)00027-5.
59. Cerasa A, Quattrone A. May hyperdirect pathway be a plausible neural substrate for understanding the rTMS-related effects on PD patients with levodopa-induced dyskinesias? Brain Stimul (2014). doi:10.1016/j.brs.2014.01.007.